Stevanato Group S.p.A. (STVN)
USD 21.72
(-1.65%)
USD 21.72
(-1.65%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 399.04 Million EUR | 82.74% |
| 2022 | 218.36 Million EUR | -10.61% |
| 2021 | 244.28 Million EUR | -32.71% |
| 2020 | 363.01 Million EUR | -3.37% |
| 2019 | 375.66 Million EUR | 18.48% |
| 2018 | 317.07 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 316.07 Million EUR | -15.61% |
| 2024 Q1 | 374.33 Million EUR | -6.19% |
| 2023 Q3 | 295.76 Million EUR | 56.67% |
| 2023 Q2 | 188.77 Million EUR | -17.04% |
| 2023 FY | 399.04 Million EUR | 82.74% |
| 2023 Q1 | 227.54 Million EUR | 4.2% |
| 2023 Q4 | 399.04 Million EUR | 34.92% |
| 2022 Q3 | 236.19 Million EUR | 1.67% |
| 2022 Q2 | 232.32 Million EUR | -6.51% |
| 2022 FY | 218.36 Million EUR | -10.61% |
| 2022 Q1 | 248.48 Million EUR | 1.72% |
| 2022 Q4 | 218.36 Million EUR | -7.55% |
| 2021 Q1 | 355.41 Million EUR | -2.09% |
| 2021 FY | 244.28 Million EUR | -32.71% |
| 2021 Q3 | 288.85 Million EUR | -13.11% |
| 2021 Q2 | 332.44 Million EUR | -6.46% |
| 2021 Q4 | 244.28 Million EUR | -15.43% |
| 2020 Q4 | 363.01 Million EUR | 0.0% |
| 2020 FY | 363.01 Million EUR | -3.37% |
| 2020 Q1 | - EUR | 0.0% |
| 2019 FY | 375.66 Million EUR | 18.48% |
| 2018 FY | 317.07 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alcon Inc. | 5.14 Billion USD | 92.241% |
| AptarGroup, Inc. | 1.18 Billion USD | 66.316% |
| Baxter International Inc. | 14.36 Billion USD | 97.222% |
| Becton, Dickinson and Company | 15.87 Billion USD | 97.487% |
| Bausch + Lomb Corporation | 4.56 Billion USD | 91.253% |
| Haemonetics Corporation | 873.88 Million USD | 54.336% |
| Envista Holdings Corp | 1.65 Billion USD | 75.868% |
| ResMed Inc. | 873.93 Million USD | 54.339% |
| Teleflex Incorporated | 1.92 Billion USD | 79.285% |
| Warby Parker Inc. | 174.45 Million USD | -128.738% |
| West Pharmaceutical Services, Inc. | 309 Million USD | -29.142% |